featured
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American College of Cardiology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
J Am Coll Cardiol 2024 Aug 20;84(8)696-708, D Edmonston, H Mulder, E Lydon, K Chiswell, Z Lampron, C Shay, K Marsolo, RC Shah, WS Jones, H Gordon, W Hwang, I Ayoub, D Ford, A Chamberlain, A Rao, V Fonseca, A Chang, F Ahmad, A Hung, K Hunt, J Butler, HB Bosworth, N PagidipatiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.